Anthera Pharmaceuticals (ANTH) 2.05 $ANTH
Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 15.94 (+0.74), BIIB: 344.49 (+2.16), IMMU: 4.58 (-0.09), RDHL: 12.98 (+0.80), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), ARGS: 8.34 (unch), NVO: 44.48 (-1.14), IDRA: 3.84 (-0.03), ANTH: 2.05 (+0.08), MRK: 57.72 (-1.62), CBMG: 14.10 (+0.12), CELGZ: 3.51 (-0.03)
Wegener's Granulomatosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 3:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/q4wq75/wegeners) has announced the addition of the "Wegener's Granulomatosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wegener's Granulomatosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wegener's Granulomatosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Wegener's Granulomatosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wegener's Granulomatosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Anthera Pharmaceuticals - Aprogen - ChemoCentryx. - Epirus Biopharmaceuticals - Panacea Biotec - Pharmapraxis - Sandoz For more information visit http://www.researchandmarkets.com/research/q4wq75/wegeners
ANTH: 2.05 (+0.08)
Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
PR Newswire - Sun Nov 23, 8:30PM CST
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update at the 2014 Annual Piper Jaffray Healthcare Conference.
ANTH: 2.05 (+0.08)
Anthera & Patheon signs manufacturing agreement for Liprotamase Phase III Registration Trial
M2 - Fri Nov 21, 5:55AM CST
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) announced on Thursday that it has entered in a manufacturing and supply agreement for Sollpura with the Patheon division of DPx Holdings BV.
ANTH: 2.05 (+0.08)
Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
PR Newswire - Thu Nov 20, 10:00AM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) announced today it has signed a manufacturing and supply agreement with the Patheon® division of DPx Holdings B.V. The contract provides for Patheon to support the production of the Sollpura® clinical drug product for Anthera's Phase III registration trial (SOLUTION - see below).
ANTH: 2.05 (+0.08)
Anthera Pharmaceuticals beats by $0.08
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 3:53PM CST
ANTH: 2.05 (+0.08)
Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update
PR Newswire - Fri Nov 14, 3:05PM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the third quarter ended September 30, 2014.
ANTH: 2.05 (+0.08)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.87 (+0.27), PCYC: 132.65 (-2.34), CLDX: 18.03 (-0.16), INCY: 74.65 (-1.27), BIND: 5.82 (+0.02), CELG: 114.49 (-2.25), OMER: 22.81 (+0.12), VSTM: 8.99 (-0.04), GILD: 104.13 (-0.18), OGXI: 2.30 (-0.04), ANTH: 2.05 (+0.08), NVAX: 5.76 (-0.17)
Anthera Pharmaceuticals Announces Update on Strategic Partnership Discussions for Blisibimod
PR Newswire - Wed Oct 01, 3:00PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States.
ANTH: 2.05 (+0.08)
4 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Oct 01, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
ROIAK: 1.45 (unch), ANTH: 2.05 (+0.08), TRXC: 1.89 (+0.07), SYMX: 0.92 (+0.01)
Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 1:50PM CDT
On Sep 25, we issued an updated research report on Qiagen N.V. (QGEN).
HSKA: 15.54 (-0.42), GILD: 104.13 (-0.18), ANTH: 2.05 (+0.08), QGEN: 22.95 (-0.29)
Genomic Health Upbeat on Strong International Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 2:00PM CDT
Genomic Health (GHDX) is focused on delivering revenue growth through constant investment for higher adoption of its tests across three major cancers
CBM: 23.66 (+0.24), GILD: 104.13 (-0.18), ANTH: 2.05 (+0.08), GHDX: 32.13 (-0.53)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ARC: 9.25 (-0.26), BIDU: 229.32 (+0.09), ANTH: 2.05 (+0.08), AMGN: 164.53 (-1.55), ALSN: 32.46 (-0.39)
Market Maker Surveillance Report. PDLI, AT, ISNS, QLTI, SINO, ANTH, Losing Stocks With Lowest Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:31AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. PDL Biopharma Inc (NASDAQ
DLI), ATLANTIC POWER CORP (NYSE:AT), Image Sensing Systems Inc (NASDAQ:ISNS), QLT INC (NASDAQ:QLTI), Sino-Global Shipping America Ltd (NASDAQ:SINO), Anthera Pharmaceuticals Inc (NASDAQ:ANTH). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
AT: 2.35 (+0.01), QLTI: 3.52 (-0.02), ANTH: 2.05 (+0.08), ISNS: 2.73 (+0.12), SINO: 1.66 (+0.02), PDLI: 7.41 (-0.08)
Anthera (ANTH) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 9:41AM CDT
Anthera (ANTH) Enters Oversold Territory
ANTH: 2.05 (+0.08)
Anthera Pharmaceuticals (ANTH) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 8:31AM CDT
Anthera Pharmaceuticals (ANTH) Sees Hammer Chart Pattern: Time to Buy?
ANTH: 2.05 (+0.08)
Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update
PR Newswire - Mon Jul 28, 4:40PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the second quarter ended June 30, 2014.
ANTH: 2.05 (+0.08)
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
PR Newswire - Mon Jul 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH-Free Report), Amgen, Inc. (Nasdaq:AMGN-Free Report), Eli Lilly and Company (NYSE:LLY-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report) and InterMune, Inc. (Nasdaq:ITMN-Free Report).
ANTH: 2.05 (+0.08), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06)
Anthera Acquires Sollpura from Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:20PM CDT
Anthera Pharmaceuticals (ANTH) acquired mid-stage development candidate, Sollpura, from Eli Lilly and Company (LLY).
ANTH: 2.05 (+0.08), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06)
Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 8:04AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise 23% on the day.
BIIB: 344.49 (+2.16), ANTH: 2.05 (+0.08), EXEL: 1.40 (unch)
Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 15.94 (+0.74), BIIB: 344.49 (+2.16), IMMU: 4.58 (-0.09), RDHL: 12.98 (+0.80), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), ARGS: 8.34 (unch), NVO: 44.48 (-1.14), IDRA: 3.84 (-0.03), ANTH: 2.05 (+0.08), MRK: 57.72 (-1.62), CBMG: 14.10 (+0.12), CELGZ: 3.51 (-0.03)
Wegener's Granulomatosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 3:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/q4wq75/wegeners) has announced the addition of the "Wegener's Granulomatosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wegener's Granulomatosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wegener's Granulomatosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Wegener's Granulomatosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wegener's Granulomatosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Anthera Pharmaceuticals - Aprogen - ChemoCentryx. - Epirus Biopharmaceuticals - Panacea Biotec - Pharmapraxis - Sandoz For more information visit http://www.researchandmarkets.com/research/q4wq75/wegeners
ANTH: 2.05 (+0.08)
Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
PR Newswire - Sun Nov 23, 8:30PM CST
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update at the 2014 Annual Piper Jaffray Healthcare Conference.
ANTH: 2.05 (+0.08)
Anthera & Patheon signs manufacturing agreement for Liprotamase Phase III Registration Trial
M2 - Fri Nov 21, 5:55AM CST
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) announced on Thursday that it has entered in a manufacturing and supply agreement for Sollpura with the Patheon division of DPx Holdings BV.
ANTH: 2.05 (+0.08)
Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
PR Newswire - Thu Nov 20, 10:00AM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) announced today it has signed a manufacturing and supply agreement with the Patheon® division of DPx Holdings B.V. The contract provides for Patheon to support the production of the Sollpura® clinical drug product for Anthera's Phase III registration trial (SOLUTION - see below).
ANTH: 2.05 (+0.08)
Anthera Pharmaceuticals beats by $0.08
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 3:53PM CST
ANTH: 2.05 (+0.08)
Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update
PR Newswire - Fri Nov 14, 3:05PM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the third quarter ended September 30, 2014.
ANTH: 2.05 (+0.08)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.87 (+0.27), PCYC: 132.65 (-2.34), CLDX: 18.03 (-0.16), INCY: 74.65 (-1.27), BIND: 5.82 (+0.02), CELG: 114.49 (-2.25), OMER: 22.81 (+0.12), VSTM: 8.99 (-0.04), GILD: 104.13 (-0.18), OGXI: 2.30 (-0.04), ANTH: 2.05 (+0.08), NVAX: 5.76 (-0.17)
Anthera Pharmaceuticals Announces Update on Strategic Partnership Discussions for Blisibimod
PR Newswire - Wed Oct 01, 3:00PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States.
ANTH: 2.05 (+0.08)
4 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Oct 01, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
ROIAK: 1.45 (unch), ANTH: 2.05 (+0.08), TRXC: 1.89 (+0.07), SYMX: 0.92 (+0.01)
Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 1:50PM CDT
On Sep 25, we issued an updated research report on Qiagen N.V. (QGEN).
HSKA: 15.54 (-0.42), GILD: 104.13 (-0.18), ANTH: 2.05 (+0.08), QGEN: 22.95 (-0.29)
Genomic Health Upbeat on Strong International Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 2:00PM CDT
Genomic Health (GHDX) is focused on delivering revenue growth through constant investment for higher adoption of its tests across three major cancers
CBM: 23.66 (+0.24), GILD: 104.13 (-0.18), ANTH: 2.05 (+0.08), GHDX: 32.13 (-0.53)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ARC: 9.25 (-0.26), BIDU: 229.32 (+0.09), ANTH: 2.05 (+0.08), AMGN: 164.53 (-1.55), ALSN: 32.46 (-0.39)
Market Maker Surveillance Report. PDLI, AT, ISNS, QLTI, SINO, ANTH, Losing Stocks With Lowest Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:31AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. PDL Biopharma Inc (NASDAQ
DLI), ATLANTIC POWER CORP (NYSE:AT), Image Sensing Systems Inc (NASDAQ:ISNS), QLT INC (NASDAQ:QLTI), Sino-Global Shipping America Ltd (NASDAQ:SINO), Anthera Pharmaceuticals Inc (NASDAQ:ANTH). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . AT: 2.35 (+0.01), QLTI: 3.52 (-0.02), ANTH: 2.05 (+0.08), ISNS: 2.73 (+0.12), SINO: 1.66 (+0.02), PDLI: 7.41 (-0.08)
Anthera (ANTH) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 9:41AM CDT
Anthera (ANTH) Enters Oversold Territory
ANTH: 2.05 (+0.08)
Anthera Pharmaceuticals (ANTH) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 8:31AM CDT
Anthera Pharmaceuticals (ANTH) Sees Hammer Chart Pattern: Time to Buy?
ANTH: 2.05 (+0.08)
Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update
PR Newswire - Mon Jul 28, 4:40PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the second quarter ended June 30, 2014.
ANTH: 2.05 (+0.08)
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
PR Newswire - Mon Jul 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH-Free Report), Amgen, Inc. (Nasdaq:AMGN-Free Report), Eli Lilly and Company (NYSE:LLY-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report) and InterMune, Inc. (Nasdaq:ITMN-Free Report).
ANTH: 2.05 (+0.08), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06)
Anthera Acquires Sollpura from Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:20PM CDT
Anthera Pharmaceuticals (ANTH) acquired mid-stage development candidate, Sollpura, from Eli Lilly and Company (LLY).
ANTH: 2.05 (+0.08), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06)
Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 8:04AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise 23% on the day.
BIIB: 344.49 (+2.16), ANTH: 2.05 (+0.08), EXEL: 1.40 (unch)
